MIRM:NSD-Mirum Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 34.43

Change

+0.55 (+1.62)%

Market Cap

USD 1.59B

Volume

0.59M

Analyst Target

USD 48.71
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing MIRM

BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.71 (+1.73%)

USD 0.02B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

+2.08 (+1.73%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.63% 75% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.63% 75% C 80% B-
Trailing 12 Months  
Capital Gain 31.56% 81% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.56% 81% B- 84% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.60% 78% C+ 83% B
Dividend Return 25.60% 78% C+ 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.51% 66% D+ 41% F
Risk Adjusted Return 60.22% 97% N/A 85% B
Market Capitalization 1.59B 86% B+ 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector